Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human B-cell lymphoma for drug discovery and mechanism of action (MOA) research

Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human B-cell lymphoma is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma.[1][2]

Detumomab is comprised of an anti-B-cell lymphomas monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-802-1mg	1mg	3090
GMP-Bios-INN-802-10mg	10mg	Inquiry
GMP-Bios-INN-802-100mg	100mg	Inquiry
GMP-Bios-INN-802-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human B-cell lymphoma
INN Name	Detumomab
Target	human B-cell lymphoma
Format	Recombinant Protein
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	0
VD LC	0
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Biogen, Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0